Saturday 17 October 2026
Export ELOX’s income statement to Excel — free account
Senesco Technologies Inc.
ELOX Healthcare Biotechnology
Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million. In the quarter to June 2026, EPS grew 87.7% and free cash flow fell 144.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
13.03
0.67
−4.89%
Follow ELOX
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
3.74 | 0.53 | 0.31 | — |
+8 more quarters Free account |
Net Debt/EBITDA |
13.95 | 1.68 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 18.98% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | (0.08) | — | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.06 | 1.45 | — | 0.93 | |
Capex/Depreciation |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
(0.71) | (1.24) | — | (5.05) | |
Cash per Share |
9.13 | 1.45 | 0.00 | 0.00 | |
Shareholders Equity per Share |
6.84 | (1.73) | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.84 | (1.73) | 0.00 | 0.00 | |
Free Cash Flow |
(4.79) | (5.45) | — | (1.75) | |
Working Capital |
46.42 | (7.58) | (11.91) | — | |
Net Current Asset Value |
46.42 | (7.58) | (11.91) | — | |
| Other line items | |||||
Quick Ratio |
3.65 | 0.40 | 0.28 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(0.71) | (1.24) | — | (5.05) | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Average Payables |
3.08 | 3.07 | 2.57 | — | |
Average Assets |
34.72 | 7.25 | 6.24 | 3.00 | |
Average Common Equity |
13.19 | (13.09) | (14.10) | — |
Columns are period end dates